Nigeria, others set to begin Lassa fever vaccine clinical trials
A new phase of Lassa fever vaccine clinical trials is set to begin in Nigeria, Liberia and Sierra Leone.
READ ALSO: Nigeria records 244 deaths from Lassa Fever in 2020
This was found in a statement on Monday released by the Public Affairs Unit of the United States Diplomatic Mission to Nigeria.
The statement said International AIDS Vaccine Initiative was awarded €22.8 million by the European and Developing Countries Clinical Trial Partnership and the Coalition for Epidemic Preparedness Innovations to conduct a Phase IIB trial of the IAVI Lassa fever vaccine candidate among adults and children in Nigeria, Liberia and Sierra Leone.
” The vaccine candidate which uses a recombinant vesicular stomatitis virus vector is now registered for use in eight African countries.
“This joint award supports an international collaboration across Africa, Europe, and North America, called the ‘Lassa Fever Vaccine Efficacy and Prevention for West Africa’ which will also strengthen the research capacity of investigational sites where Lassa fever outbreaks and disease occur frequently.
“In Nigeria, HJFMRI will conduct the study at its Clinical Research Centre (CRC) supported by the Walter Reed Army Institute of Research,” the statement showed.
MTO/Punch
